title: Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.
abstract: Vascular endothelial growth factor (VEGF)-induced endothelial cell migration is an important component of tumor angiogenesis. Rho and Rho-associated kinase (ROCK) are key regulators of focal adhesion, stress fiber formation, and thus cell motility. Inhibitors of this pathway have been shown to inhibit endothelial cell motility and angiogenesis. In this study, we investigated the antiangiogenic effect of fasudil, one of the ROCK inhibitors. Fasudil inhibited VEGF-induced endothelial cell migration, viability, and tube formation in vitro in human umbilical vein endothelial cells. VEGF-induced endothelial cell migration was reduced by fasudil associated with loss of stress fiber formation, focal adhesion assembly, and with the suppression of tyrosine phosphorylation of focal adhesion proteins. Furthermore, fasudil inhibited VEGF-induced phosphorylation of myosin light chain, which is one of the main substrates of ROCK. Therefore, the effect of fasudil was suggested to be ROCK dependent. Fasudil not only inhibited VEGF-induced cell proliferation but also reversed the protective effect of VEGF on apoptosis, which resulted in the decrease of cell viability. Moreover, fasudil inhibited VEGF-induced angiogenesis in a directed in vivo angiogenesis assay. These data are the first demonstration that fasudil has antiangiogenic properties. Therefore, fasudil might be useful for the treatment of angiogenesis-related diseases, especially cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
authors.forename: Limei
authors.initials: L
authors.lastname: Yin
authors.forename: Ken-Ichirou
authors.initials: K
authors.lastname: Morishige
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Kae
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Seiji
authors.initials: S
authors.lastname: Ogata
authors.forename: Seiji
authors.initials: S
authors.lastname: Tsutsumi
authors.forename: Keiko
authors.initials: K
authors.lastname: Takata
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ohta
authors.forename: Jun
authors.initials: J
authors.lastname: Kawagoe
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takahashi
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Kurachi
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis; D002465:Cell Movement; D049109:Cell Proliferation; D002470:Cell Survival; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D051379:Mice; D009389:Neovascularization, Pathologic; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D014471:Umbilical Veins; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D054460:rho-Associated Kinases
chemical_list: D020533:Angiogenesis Inhibitors; D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases; C049347:fasudil